Life Science Compliance Update

May

2016

Peeling Back the Olympus Onion – The Importance of Culture

Written by , Posted in Compliance culture

Kathleen Drennan, Esq., Staff Writer for Life Science Compliance Update
This article examines an apparent breakdown in corporate culture that goes beyond the subsidiaries to the parent company, Olympus Corporation. It is a cautionary tale for life science compliance officers on the importance of corporate culture’s impact on successful (or in this case unsuccessful) compliance.


   or   

Topic tags:

March

2016

A Prescription for Life Science’s Regulatory Woes

Written by , Posted in Compliance culture

By: Tracey Keele, Partner, KPMG Risk Consulting

The life sciences industry continues to face a crisis of reputation. This article explores that crisis and suggests that the search for the solution may lie in organizational culture and a better understanding of behavioral ethics.


   or   

Topic tags:

March

2016

Do Gold-Standard CIAs Get Blue Ribbon Approval?

Written by , Posted in Compliance culture

By: Calisha D. Myers, Esq., Staff Writer

Corporate Integrity Agreements are thought to set the standard for compliance programs, but when viewed against the norms set out by a new report from the Ethics and Compliance Initiative’s Blue Ribbon Panel, CIAs fall short. This article is the first in a series examining the gap between the compliance programs outlined in CIAs and the Blue Ribbon Panel ethics and compliance (E&C) guidelines, and what companies can do to move their program from a CIA-standards based program to a Blue Ribbon “high-quality” E&C program.


   or   

Topic tags:

Gravityscan Badge
Menu Title